

1                   **SARS Coronavirus-2 microneutralisation and commercial**  
2                   **serological assays correlated closely for some but not all enzyme**  
3                   **immunoassays**

4 Gregory J Walker <sup>1,2</sup>, Zin Naing <sup>3</sup>, Alberto Ospina Stella <sup>4</sup>, Malinna Yeang <sup>1,3</sup>, Joanna  
5 Caguicla <sup>3</sup>, Vidiya Ramachandran <sup>3</sup>, Sonia R Isaacs <sup>1</sup>, David Agapiou <sup>4</sup>, Rowena A  
6 Bull <sup>4</sup>, Sacha Stelzer-Braid <sup>1,2</sup>, James Daly <sup>5</sup>, Iain B Gosbell <sup>5,6</sup>, Veronica C Hoad <sup>5</sup>,  
7 David O Irving <sup>5,7</sup>, Joanne M Pink <sup>5</sup>, Stuart Turville <sup>4</sup>, Anthony D Kelleher <sup>4</sup>, William D  
8 Rawlinson <sup>1,2,3,8</sup>

9  
10 **Affiliations:**

11 <sup>1</sup> *Virology Research Laboratory, Prince of Wales Hospital, Sydney, NSW 2031,*  
12 *Australia*

13 <sup>2</sup> *School of Medical Sciences, and School of Women's and Children's Health, Faculty*  
14 *of Medicine, University of New South Wales, Sydney, NSW 2052, Australia*

15 <sup>3</sup> *Serology and Virology Division (SaViD), NSW Health Pathology, Prince of Wales*  
16 *Hospital, Sydney, NSW 2031, Australia*

17 <sup>4</sup> *Kirby Institute, University of New South Wales, Sydney, NSW 2052, Australia*

18 <sup>5</sup> *Australian Red Cross Lifeblood, 417 St Kilda Rd, Melbourne, Victoria 3004,*  
19 *Australia*

20 <sup>6</sup> *School of Medicine, Western Sydney University, Penrith, NSW, Australia*

21 <sup>7</sup> *Faculty of Health, University of Technology, Sydney*

22 <sup>8</sup> *School of Biotechnology and Biomolecular Sciences, Faculty of Science, University*  
23 *of New South Wales, Sydney, NSW 2052, Australia*

24 **\*Corresponding author:** Prof William Rawlinson, Virology Research Laboratory,  
25 Level 3 Clinical Sciences Building, Prince of Wales Hospital, Randwick 2031,  
26 Australia.

27 **E-mail:** w.rawlinson@unsw.edu.au      **Ph:** +61 2 93829188

28

29 **Alternate contact:** Gregory Walker, Virology Research Laboratory, Level 3 Clinical  
30 Sciences Building, Prince of Wales Hospital, Randwick 2031, Australia.

31 **Email:** gregory.walker@unsw.edu.au      **Ph:** +61 2 93829096

32

33 **Running title:** Detection of SARS-CoV-2 neutralising antibody

## 34 **Abstract**

### 35 *Background*

36 Serological testing for SARS-CoV-2 specific antibodies provides important research  
37 and diagnostic information relating to COVID-19 prevalence, incidence, and host  
38 immune response. A greater understanding of the relationship between functionally  
39 neutralising antibodies detected using microneutralisation assays and binding  
40 antibodies detected using scalable enzyme immunoassays (EIA) is needed in order  
41 to address protective immunity post-infection or vaccination, and assess EIA  
42 suitability as a surrogate test for screening of convalescent plasma donors. We  
43 assessed whether neutralising antibody titres correlated with signal cut-off ratios in  
44 five commercially available EIAs, and one in-house assay based on expressed spike  
45 protein targets.

### 46 *Methods*

47 Sera from individuals recovered from patients or convalescent plasma donors who  
48 reported laboratory-confirmed SARS-CoV-2 infection (n=200), and negative control  
49 sera collected prior to the COVID-19 pandemic (n=100) were assessed in parallel.  
50 Performance was assessed by calculating EIA sensitivity and specificity with  
51 reference to microneutralisation.

### 52 *Results*

53 Neutralising antibodies were detected in 166 (83%) samples. Compared with this,  
54 the most sensitive EIAs were the Cobas Elecsys Anti-SARS-CoV-2 (98%) and Vitros  
55 Immunodiagnostic Anti-SARS-CoV-2 (100%), which detect total antibody targeting  
56 the N and S1 antigens, respectively. The assay with the best quantitative relationship  
57 with microneutralisation was the Euroimmun IgG.

58 *Conclusions*

59 These results suggest the marker used (total Ab vs IgG vs IgA), and the target  
60 antigen are important determinants of assay performance. The strong correlation  
61 between microneutralisation and some commercially available assays demonstrate  
62 their potential for clinical and research use in assessing protection following infection  
63 or vaccination, and use as a surrogate test to assess donor suitability for  
64 convalescent plasma donation.

65

66 **Keywords**

67 SARS-CoV-2, neutralising antibody, serology, COVID-19, convalescent plasma

68

69

70 **Introduction**

71 The easing of COVID-19 control measures requires extensive surveillance for the  
72 early detection of new clusters, as well as an understanding of the level and duration  
73 of protective immunity in the community. Serological testing for SARS-CoV-2 specific  
74 antibodies is an important tool that serves multiple diagnostic and research purposes  
75 including: i) confirmation of suspected infection, ii) informing public health policy by  
76 determining the true infection rate (symptomatic and asymptomatic cases) occurring  
77 within a population, iii) assessing seroconversion following infection or vaccination  
78 and iv) as a potential scalable screening test to determine suitability for convalescent  
79 plasma donation (1-4).

80 It is important to decipher the neutralising capability of developed SARS-CoV-2  
81 specific antibodies to understand whether the host response will provide sufficient  
82 protection from future reinfection. Neutralising antibodies can be detected using the  
83 microneutralisation assay and plaque reduction neutralisation test. These assess the  
84 ability of patient-derived serum samples containing SARS-CoV2 specific antibody to  
85 inhibit infection of cells cultured in vitro (5). These virus neutralisation tests require  
86 the handling of replication-competent SARS-CoV-2 in specialized containment  
87 laboratories (biosafety level 3, at minimum (6)), and for this reason are impractical to  
88 scale. Commercially available serology tests such as enzyme immunoassays (EIA)  
89 are faster and less laborious than traditional culture-based methods, which is  
90 advantageous in the diagnostic laboratory setting (7). However, these assays do not  
91 differentiate between binding antibodies and neutralising antibodies (8). The  
92 detection of binding antibodies does not necessarily confer virus-neutralisation or  
93 protection against virus replication in the infected host, and traditional virus  
94 neutralisation tests remain the reference standard (9). Correlation of binding

95 antibodies detected using EIA with neutralising antibody titres will be crucial for  
96 population-level screening of seroconversion and assessment of herd-immunity  
97 following vaccination and rapid assessment of the suitability of convalescent plasma  
98 donors (4, 10).

99 In response to demand for SARS-CoV-2 serological testing kits, numerous assays  
100 have been released under relaxed regulatory assessment criteria (1). Validation  
101 studies by end-users are important to assess the performance characteristics of  
102 these new commercial assays, and to determine the correlation between EIAs and  
103 neutralising antibody titres. To date, a small number of studies have validated a  
104 range of commercially available SARS-CoV-2 serological assays against a live-virus  
105 neutralisation test (11-15). Assays assessed in these publications incorporate  
106 automated platforms as well as serology-based point of care tests and have some,  
107 but limited crossover with the comparison of EIAs in the present study. Others tested  
108 too few samples to effectively correlate EIA results with neutralising antibody titres  
109 (16-20), lacked comparison of head-to-head EIAs (21, 22), or used live-virus  
110 neutralisation as a reference standard primarily to validate assays developed in-  
111 house (23-26). Here we report on the performance of a unique set of five  
112 commercially available SARS-CoV-2 serological assays and an in-house developed  
113 EIA, with reference to a reference-standard microneutralisation assay.

114

115

116

117

## 118 **Methods**

### 119 *Sample collection and testing*

120 All samples were received by the Serology and Virology Division at the Prince of  
121 Wales Hospital Randwick, Australia. Two hundred sera were collected from  
122 laboratory-confirmed COVID-19 patients (n=157) between March and June of 2020.  
123 The majority were recruited as convalescent plasma donors (self-reported laboratory  
124 confirmed infection) and tested as part of the release test to ensure donor suitability  
125 on behalf of Australian Red Cross Lifeblood (161 samples from 124 donors). Donor  
126 samples were collected 37 to 101 days post- test positivity date (mean=60.5). The  
127 donors ranged in age from 20 to 78 years old (mean =45.3 years) with 54.6% being  
128 males. A smaller proportion of serum (39/200), were obtained from COVID-19  
129 patients 1 to 47 days post- laboratory-confirmed diagnosis. An additional 100 sera  
130 were obtained from patients prior to the COVID-19 pandemic between 2016 and  
131 2018 (control cohort). This included 25/100 samples serologically positive for  
132 antibodies to common respiratory viruses (Supplementary Table 1). Antibodies to  
133 SARS-CoV-2 in samples were measured using a microneutralisation assay at two  
134 dilutions (1:40 and 1:80), and up to six other immunoassays including an in-house  
135 developed EIA. Commercially available assays were performed according to the  
136 manufacturer's instructions, using kits of the same lot number for all assays.  
137 Samples returning equivocal/borderline results (as per the manufacturer-specified  
138 range) were not included in sensitivity and specificity calculations.

139

### 140 *Virus microneutralisation assay*

141 Dilutions of test serum were prepared on a 96-well plate in duplicate in viral culture  
142 media (MEM + 2% fetal bovine serum + 1x penicillin-streptomycin-glutamine). The  
143 dilutions were incubated for one hour at 37°C with an equal volume of 200 TCID<sub>50</sub>  
144 SARS-CoV-2 isolate. A suspension of Vero E6 cells containing 2x10<sup>4</sup> cells was  
145 added to each well, and plates were incubated at 37°C (5% CO<sub>2</sub>) for three days. The  
146 plates were observed for cytopathic effect and the neutralisation titre determined as  
147 the dilution that conferred complete protection from infection in both replicates.  
148 Neutralising titres of 1:40 and above were considered positive.

149

#### 150 *Cobas Elecsys Anti-SARS-CoV-2*

151 The Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Australia) is an  
152 electrochemiluminescence immunoassay (ECLIA) for the detection of total antibody  
153 against the N protein of SARS-CoV-2 in serum and plasma. The platform provided a  
154 readout indicating whether the sample measurement is above or below the signal  
155 cutoff, and was interpreted as positive ( $\geq 1.0$ ) or negative ( $< 1.0$ ).

156

#### 157 *Vitros Immunodiagnostic Anti-SARS-CoV-2*

158 The Vitros Immunodiagnostic Anti-SARS-CoV-2 (Ortho-Clinical Diagnostics,  
159 Australia) is a chemiluminescent immunoassay (CLIA) utilizing a recombinant SARS-  
160 CoV-2 S1 protein to measure total antibody present in serum and plasma. The  
161 platform provided a readout indicating whether the sample measurement was above  
162 or below the signal cutoff, and was interpreted as positive ( $\geq 1.0$ ) or negative ( $< 1.0$ ).

163

164 *Abbott Architect SARS-CoV-2 IgG*

165 The Architect SARS-CoV-2 IgG (Abbott Diagnostics, Australia) is a chemiluminescent  
166 microparticle immunoassay (CMIA) for the detection of IgG antibodies to the  
167 nucleocapsid (N) protein of SARS-CoV-2 in serum and plasma. The platform  
168 calculated a result by dividing the chemiluminescent signal from each sample with a  
169 calibrated signal. The unit for the assay is Index (S/C) and the result was interpreted  
170 as positive ( $\geq 1.4$ ) or negative ( $< 1.4$ ).

171

172 *Euroimmun Anti-SARS-CoV-2 ELISA*

173 The Anti-SARS-CoV-2 (Euroimmun, Germany) is an enzyme linked immunosorbent  
174 assay (ELISA) based platform that utilizes recombinant S1 protein to bind anti-  
175 SARS-CoV-2 antibodies in serum or plasma. Separate kits for the detection of IgG  
176 and IgA were used. Photometric measurement of colour intensity was used to  
177 calculate a ratio of the sample over the calibrator. The ratio was interpreted as  
178 positive ( $\geq 1.1$ ), borderline ( $\geq 0.8 - < 1.1$ ), or negative ( $< 0.8$ ).

179

180 *In-house RBD assay*

181 The in-house ELISA was performed by coating 96-well microtiter ELISA plates with  
182 biotinylated RBD antigen (Supplementary information), which bound SARS-CoV-2  
183 specific antibodies. Diluted serum (1:101) or controls were added to respective wells  
184 for one hour. Wells were aspirated and washed three times with wash solution (PBS  
185 + 1% Tween 20). A secondary antibody (antihuman-IgG conjugated with the enzyme  
186 alkaline phosphatase, Virion/Serion) was then added to wells for 30 minutes to

187 detect and bind the immune complex. The wash step was then repeated, before the  
188 addition of substrate solution (p-nitrophenylphosphate, Virion/Serion) for 30 minutes.  
189 The stopping solution was then added (<0.1 N sodium hydroxide and 40 mM EDTA,  
190 Virion/Serion) and absorbance was read at 405/620 nm. The cutoff optical density  
191 (OD) was set at 0.2 above the negative control OD. Samples were considered  
192 positive if the absorbance value was equal to or higher than the cutoff value.

193

#### 194 *Statistical Analyses*

195 The performance of the commercial assays were compared using results of the  
196 microneutralisation assay as the reference-standard. For sensitivity, only  
197 microneutralisation-positive samples were used in calculations. Assay specificity and  
198 cross-reactivity were assessed using samples from the negative-control cohort.  
199 Equivocal results were excluded from sensitivity and specificity calculations. Figures  
200 including optical density ratios and ROC curves were generated in GraphPad Prism  
201 9. For the purpose of this analysis, serum collected  $\geq 14$  days post- laboratory  
202 confirmed COVID-19 diagnosis was considered convalescent.

203 Ethics approval to compare and validate antibody SARS-CoV-2 assays as part of a  
204 larger project to collect, manufacture and supply convalescent plasma to patients  
205 enrolled in clinical trials and for COVID-19 Immunoglobulin was approved by the  
206 Lifeblood Ethics Committee (approval number Hoad 30042020).

207 **Results**

208 Neutralising antibodies were detected in 166/200 (83%) COVID-19 confirmed sera  
209 (Table 1). There were 151/167 (90%) convalescent sera ( $\geq 14$  days) positive for  
210 neutralising antibodies including 112 (67%) which were neutralising at the highest  
211 dilution tested (1:80). No samples in the control cohort were positive for neutralising  
212 antibodies.

213 Across all assays SARS-CoV-2 antibodies were detected in 182/200 (91%) samples  
214 tested, with individual EIA positivity ranging between 61-90% (Table 1). There were  
215 five convalescent sera from NAT-confirmed COVID-19 patients that returned  
216 negative results by microneutralisation and all EIAs tested (samples tested on  $\geq 3$   
217 EIAs).

218 The sensitivity values of the commercially available assays against the  
219 microneutralisation reference-standard ranged from 69-100%, with assays  
220 measuring total antibody being most sensitive (Table 1). There was little difference in  
221 the sensitivity of assays in detecting neutralising antibody between acute and  
222 convalescent COVID-19 samples. Optical density ratios for each EIA, at varying  
223 neutralising antibody titres are shown in Figure 1. The Euroimmun IgG assay had the  
224 highest positive predictive value (94%) and displayed the best quantitative  
225 relationship with microneutralisation (Figure 2). All EIAs other than the Euroimmun  
226 IgA (94%) and in-house ELISA (96%) displayed 100% specificity in testing the  
227 negative control cohort.

228

229

## 230 **Discussion**

231 Serological assays need to have validated performance characteristics in assessing  
232 SARS CoV-2 infection for diagnosis, surveillance and correlation with other assays.  
233 Given neutralisation activity is important for immunity and for potential therapeutic  
234 options such as convalescent plasma and immunoglobulin production, the major  
235 strength of our study is that it is one of the few to validate serological assays for  
236 SARS-CoV-2 against a virus neutralisation test. On reference testing, neutralising  
237 antibodies were detected in 83% of samples, compared to EIA which detected  
238 SARS-CoV-2 antibodies in 91% of samples across all assays. This was unsurprising  
239 considering that not all patients with COVID-19 develop neutralising antibodies to  
240 infection (27). For this reason, all assays produced false positives in reference to  
241 microneutralisation, with Euroimmun IgG displaying the highest positive predictive  
242 value and best correlation with neutralising antibody titres. Clinically, EIAs that  
243 correlate strongly with microneutralisation are of importance considering that the  
244 detection of neutralising antibodies may be useful in informing return to work and the  
245 discontinuation of transmission-based precautions (1).

246 For the aim of detecting protective neutralising antibodies, the S1-based Vitros  
247 Immunodiagnostic and the N-based Cobas Elecsys assays were most sensitive. A  
248 previous study suggested that assays targetting RBD and N proteins were more  
249 sensitive and better correlated with neutralisation titres than those targetting the S1  
250 protein (23). Our testing of 300 samples found assay sensitivity to be dependent on  
251 assay marker (total Ab vs IgG vs IgA), and quantitative relationship dependent on  
252 the target antigen used – with the three spike-based assays best correlating with  
253 neutralising antibody titre (Figure 2).

254 In line with other validation studies using composite reference standards (28-30), the  
255 Euroimmun anti-SARS-CoV-2 IgG ELISA was highly sensitive and specific.  
256 However, the reported performance of the Euroimmun anti-SARS-CoV-2 IgA ELISA  
257 is mixed, and here we found it to have low sensitivity. IgG response is longer lived  
258 (31) and these findings may be reflective of our cohort, which was primarily made up  
259 of convalescent serum collected more than 36 days following laboratory-confirmed  
260 infection. The performance of the Architect IgG assay in detecting neutralising  
261 antibody was moderate, and in convalescent samples positivity was well below the  
262 sensitivity values advertised by the manufacturer (74% vs 100%). This highlights the  
263 importance of independent validation studies comparing a range of assays against  
264 multiple reference standards. Interestingly, there were five convalescent sera from  
265 reported laboratory-confirmed COVID-19 patients that returned negative results by  
266 microneutralisation and all EIAs tested. This also occurred in a validation study and  
267 could be explained by a failure to develop a measureable systemic antibody  
268 response, clearance of infection via other immune mechanisms, or an initial false-  
269 positive RT-qPCR result (32). Whilst donors in our study were required to confirm  
270 they had laboratory confirmed infection to donate, proof in terms of visualisation of a  
271 hard copy of the donors' results did not occur. Therefore it is possible that donors  
272 were non-compliant, or that the five samples in our study that were negative on all  
273 assays had a biological absence of antibodies.

274 All assays other than Euroimmun IgA displayed excellent specificity in testing a  
275 control cohort of pre-COVID-19 sera. The control cohort also included a small panel  
276 of non-SARS-CoV-2 sera positive for other respiratory virus antibodies, and we  
277 found no cross-reactivity on any of the assays used. Others have suggested that S1  
278 and N are highly specific targets for SARS-CoV-2 serological analyses (23), and

279 these antigens largely form the basis of current commercially available assays. A  
280 limitation of this work is that the timing of serum collection was not standardised, and  
281 that samples obtained were not tested equally across all assays due to limitations in  
282 sample volume and dead volume requirements of the automated EIAs. Nonetheless,  
283 the relatively large number of samples run remains a strength of this study, and  
284 allows for a head-to-head comparison of commercially available SARS-CoV-2  
285 serological tests seen in few other studies.

286 We and others have shown that commercially available serological assays for  
287 SARS-CoV-2 have varying performance that is dependent on both the platform and  
288 marker used. The assay chosen by end-users should be tailored to specific  
289 applications - for example, assays measuring antibodies to the nucleocapsid antigen  
290 might be best suited to disease surveillance as spike-protein based vaccines  
291 become available. During the COVID-19 pandemic, serological assays will be crucial  
292 in answering questions of immune protection against reinfection. If convalescent  
293 plasma or COVID-19 immunoglobulin is found to be a potentially effective  
294 therapeutic intervention, high throughput serological assays that closely correlate  
295 with neutralisation antibody levels are vital for scalability. As further testing platforms  
296 become available, validation studies such as this are needed to identify assays that  
297 inform on antibody titre and functionality.

298

299 **Funding**

300 No specific funding was provided for this study.

301

302 **Acknowledgements**

303 The authors would like to thank the Clinical Chemistry Laboratory at the Prince of  
304 Wales Hospital Randwick, the Reproductive Endocrinology Laboratory at the Royal  
305 Hospital for Women Randwick, and University of New South Wales Stats Central for  
306 their generous technical support. Australian Governments fund Australian Red Cross  
307 Lifeblood for the provision of blood, blood products and services to the Australian  
308 community.

309

310

311 **References**

- 312 1. Petherick A. Developing antibody tests for SARS-CoV-2. *The Lancet*.  
313 2020;395(10230):1101-2
- 314 2. Krammer F, Simon V. Serology assays to manage COVID-19. *Science*.  
315 2020;368(6495):1060-1.
- 316 3. Peeling RW, Wedderburn CJ, Garcia PJ, et al. Serology testing in the COVID-  
317 19 pandemic response. *The Lancet Infectious Diseases*. 2020;20(9):e245-e9.
- 318 4. Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma  
319 for treatment of moderate and severe pneumonia in COVID-19 patients and  
320 association with IgG antibody levels in donated plasma. *EClinicalMedicine*. 2020;26.
- 321 5. Henderson JR, Taylor RM. Arthropod-Borne Virus Plaques in Agar Overlaid  
322 Tube Cultures. *Proc Soc Exp Biol Med*. 1959;101(2):257-9.
- 323 6. Stelzer-Braid S, Walker GJ, Aggarwal A, et al. Virus isolation of severe acute  
324 respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research  
325 purposes. *Pathology (Phila)*. 2020.
- 326 7. D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel  
327 Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). *Frontiers in Cell  
328 and Developmental Biology*. 2020;8(468).
- 329 8. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization  
330 test based on antibody-mediated blockage of ACE2–spike protein–protein  
331 interaction. *Nat Biotechnol*. 2020.
- 332 9. Klasse PJ. Neutralization of Virus Infectivity by Antibodies: Old Problems in  
333 New Perspectives. *Advances in Biology*. 2014;2014:157895.
- 334 10. Houlihan CF, Beale R. The complexities of SARS-CoV-2 serology. *The  
335 Lancet Infectious Diseases*. 2020.

- 336 11. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19  
337 serological assays informs future diagnostics and exposure assessment. *Nature*  
338 *Communications*. 2020;11(1):3436.
- 339 12. Henss L, Scholz T, von Rhein C, et al. Analysis of humoral immune  
340 responses in SARS-CoV-2 infected patients. *J Infect Dis*. 2020.
- 341 13. Luchsinger LL, Ransegnola B, Jin D, et al. Serological Assays Estimate  
342 Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19  
343 Patients. *J Clin Microbiol*. 2020:JCM.02005-20.
- 344 14. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five  
345 commercially available serologic assays to detect antibodies to SARS-CoV-2 and  
346 identify individuals with high neutralizing titers. *J Clin Microbiol*. 2020:JCM.02257-20.
- 347 15. Weidner L, Gänsdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2  
348 antibodies with eight commercially available immunoassays. *J Clin Virol*.  
349 2020;129:104540.
- 350 16. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, et al. Performance of six SARS-  
351 CoV-2 immunoassays in comparison with microneutralisation. *Journal of clinical*  
352 *virology : the official publication of the Pan American Society for Clinical Virology*.  
353 2020;129:104512-.
- 354 17. Brigger D, Horn MP, Pennington LF, et al. Accuracy of serological testing for  
355 SARS-CoV-2 antibodies: first results of a large mixed-method evaluation study.  
356 *Allergy*. 2020:10.1111/all.14608.
- 357 18. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical  
358 evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *Journal of*  
359 *clinical virology : the official publication of the Pan American Society for Clinical*  
360 *Virology*. 2020;129:104480-.

- 361 19. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Clinical performance  
362 of different SARS-CoV-2 IgG antibody tests. *J Med Virol.* 2020;92(10):2243-7.
- 363 20. Marklund E, Leach S, Axelsson H, et al. Serum-IgG responses to SARS-CoV-  
364 2 after mild and severe COVID-19 infection and analysis of IgG non-responders.  
365 *PloS one.* 2020;15(10):e0241104-e.
- 366 21. Lumley SF, Eyre DW, McNaughton AL, et al. SARS-CoV-2 antibody  
367 prevalence, titres and neutralising activity in an antenatal cohort, United Kingdom, 14  
368 April to 15 June 2020. *Eurosurveillance.* 2020;25(42):2001721.
- 369 22. Meschi S, Colavita F, Bordi L, et al. Performance evaluation of Abbott  
370 ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect  
371 immunofluorescence and virus microneutralization test. *Journal of clinical virology :*  
372 *the official publication of the Pan American Society for Clinical Virology.*  
373 2020;129:104539-.
- 374 23. Okba NMA, Müller M, Li W, et al. Severe Acute Respiratory Syndrome  
375 Coronavirus 2–Specific Antibody Responses in Coronavirus Disease Patients.  
376 *Emerging Infectious Disease journal.* 2020;26(7):1478.
- 377 24. Grzelak L, Temmam S, Planchais C, et al. A comparison of four serological  
378 assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from  
379 different populations. *Sci Transl Med.* 2020;12(559).
- 380 25. Padoan A, Bonfante F, Sciacovelli L, Cosma C, Basso D, Plebani M.  
381 Evaluation of an ELISA for SARS-CoV-2 antibody testing: clinical performances and  
382 correlation with plaque reduction neutralization titer. *Clinical Chemistry and*  
383 *Laboratory Medicine (CCLM).* 2020;58(11):e247.

- 384 26. Peterhoff D, Glück V, Vogel M, et al. A highly specific and sensitive  
385 serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that  
386 correlate with neutralization. *Infection*. 2020:1-8.
- 387 27. Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses  
388 to SARS-CoV-2 in convalescent individuals. *Nature*. 2020;584(7821):437-42.
- 389 28. Beavis KG, Matushek SM, Abeleda APF, et al. Evaluation of the  
390 EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG  
391 antibodies. *Journal of clinical virology : the official publication of the Pan American  
392 Society for Clinical Virology*. 2020;129:104468-.
- 393 29. Haselmann V, Kittel M, Gerhards C, et al. Comparison of test performance of  
394 commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples. *Clin  
395 Chim Acta*. 2020;510:73-8.
- 396 30. Charlton CL, Kanji JN, Johal K, et al. Evaluation of six commercial mid to high  
397 volume antibody and six point of care lateral flow assays for detection of SARS-CoV-  
398 2 antibodies. *J Clin Microbiol*. 2020:JCM.01361-20.
- 399 31. Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution  
400 of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated  
401 coronavirus. *Clin Microbiol Infect*. 2004;10(12):1062-6.
- 402 32. Ainsworth M, Andersson M, Auckland K, et al. Performance characteristics of  
403 five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *The  
404 Lancet Infectious Diseases*.
- 405

**Table 1.** Performance of commercially available SARS-CoV-2 serological assays

	<b>Microneutralisation</b>	<b>Cobas total Ab</b>	<b>Vitros total Ab</b>	<b>Abbott IgG</b>	<b>In-house IgG</b>	<b>Euroimmun IgG</b>	<b>Euroimmun IgA</b>
<b>Platform</b>	Cell culture	ECLIA	CLIA	CMIA	ELISA	ELISA	ELISA
<b>Antigen</b>	-	N	S1	N	RBD	S1	S1
<b>All COVID-19 samples</b>							
Total	200	197	98	199	94	132	96
Positive	166	175	88	139	79	106	51
Negative	34	22	10	60	11	24	32
Equivocal	-	-	-	-	4	2	13
Positivity (%)	83.0	88.8	89.8	69.8	87.8	81.5	61.4
Sensitivity <sup>1</sup> (%)	-	98.2	100.0	78.8	96.1	94.3	69.4
<b>Convalescent samples<sup>2</sup></b>							
Total	167	167	73	167	74	109	73
Positive	151	160	72	123	65	93	40
Negative	16	70	1	43	6	66	24
Equivocal	-	-	-	-	3	2	9
Positivity (%)	90.4	95.8	98.6	73.7	91.5	86.9	62.5
Sensitivity <sup>1</sup> (%)	-	98.7	100.0	76.8	95.3	93.6	65.0
<b>Negative samples</b>							
Total	100	100	99	100	100	100	100
Positive	0	0	0	0	4	0	6
Negative	100	100	99	100	96	100	92
Equivocal	-	-	-	-	-	-	2
Specificity <sup>1</sup> (%)	100.0	100.0	100.0	100.0	96.0	100.0	93.9
<b>PPV (%)</b>	-	93.7	90.9	93.5	89.2	94.3	87.7
<b>NPV (%)</b>	-	97.5	100.0	78.1	97.2	95.1	77.3


<sup>1</sup> Sensitivity and specificity calculated against reference-standard virus neutralisation test

<sup>2</sup> Samples were considered convalescent if they were collected  $\geq 14$  days post-NAT detection

Equivocal results were excluded from sensitivity and specificity calculations

ECLIA, electrochemiluminescence immunoassay; CLIA, chemiluminescent immunoassay; CMIA, chemiluminescent microparticle immunoassay; ELISA, enzyme linked immunosorbent assay; N, nucleoprotein; S1, spike glycoprotein subunit 1; RBD, receptor binding domain; PPV, positive predictive value; NPV, negative predictive value






1

2 **Figure 1.** Optical density ratios of SARS-CoV-2 enzyme immunoassays (EIA) at  
3 varying neutralising antibody titres. Serum from COVID-19 confirmed patients were  
4 assayed using microneutralisation and (A) Cobas Elecsys Anti-SARS-CoV-2, (B)

5 Vitros Immunodiagnostic Anti-SARS-CoV-2, (C) Abbott Architect SARS-CoV-2 IgG,  
6 (D) an In-house IgG ELISA, (E) Euroimmun Anti-SARS-CoV-2 IgG ELISA, and (F)  
7 Euroimmun Anti-SARS-CoV-2 IgA ELISA. Dashed line indicates the positive cut-off  
8 value of each assay determined by the manufacturer. The width of the scatter plot is  
9 proportionate to the number of data points at a given value, and the median EIA  
10 optical density shown. OD, optical density.

11

12



13

14 **Figure 2.** ROC curves for each enzyme immunoassay (A) Cobas Elecsys Anti-  
15 SARS-CoV-2, (B) Vitros Immunodiagnostic Anti-SARS-CoV-2, (C) Abbott Architect  
16 SARS-CoV-2 IgG, (D) an In-house IgG ELISA, (E) Euroimmun Anti-SARS-CoV-2  
17 IgG ELISA, and (F) Euroimmun Anti-SARS-CoV-2 IgA ELISA. Note: Data are

18 presented for up to 200 COVID-19 confirmed sera using microneutralisation as the  
19 reference-standard. Euroimmun IgG had the best correlation with the detection of  
20 neutralising antibody (AUC= 0.9525). Dashed line represents assay performance at  
21 the positive cut-off value specified by the manufacturer. ROC, receiver operating  
22 characteristic; AUC, area under curve.

23